In skeletal muscle excitation–contraction (E–C) coupling, depolarization of the plasma membrane triggers Ca2+ release from the sarcoplasmic reticulum (SR), referred to as depolarization-induced Ca2+ release (DICR). DICR occurs through the type 1 ryanodine receptor (RyR1), which physically interacts with the dihydropyridine receptor Cav1.1 subunit in specific machinery formed with additional essential components including β1a, Stac3 adaptor protein, and junctophilins. Exome sequencing has accelerated the discovery of many novel mutations in genes encoding DICR machinery in various skeletal muscle diseases. However, functional validation is time-consuming because it must be performed in a skeletal muscle environment. In this study, we established a platform of the reconstituted DICR in HEK293 cells. The essential components were effectively transduced into HEK293 cells expressing RyR1 using baculovirus vectors, and Ca2+ release was quantitatively measured with R-CEPIA1er, a fluorescent ER Ca2+ indicator, without contaminant of extracellular Ca2+ influx. In these cells, [K+]-dependent Ca2+ release was triggered by chemical depolarization with the aid of inward rectifying potassium channel, indicating a successful reconstitution of DICR. Using the platform, we evaluated several Cav1.1 mutations that are implicated in malignant hyperthermia and myopathy. We also tested several RyR1 inhibitors; whereas dantrolene and Cpd1 inhibited DICR, procaine had no effect. Furthermore, twitch potentiators such as perchlorate and thiocyanate shifted the voltage dependence of DICR to more negative potentials without affecting Ca2+-induced Ca2+ release. These results well reproduced the findings with the muscle fibers and the cultured myotubes. Since the procedure is simple and reproducible, the reconstituted DICR platform will be highly useful for the validation of mutations and drug discovery for skeletal muscle diseases.
Skip Nav Destination
Article navigation
5 December 2022
Methods and Approaches|
November 01 2022
A reconstituted depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery
Takashi Murayama
,
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Correspondence to Takashi Murayama: takashim@juntendo.ac.jp
Search for other works by this author on:
Nagomi Kurebayashi
,
Nagomi Kurebayashi
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Takuro Numaga-Tomita,
Takuro Numaga-Tomita
2
Department of Molecular Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
Search for other works by this author on:
Takuya Kobayashi,
Takuya Kobayashi
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Satoru Okazaki,
Satoru Okazaki
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Kyosuke Yamashiro,
Kyosuke Yamashiro
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Tsutomu Nakada
,
Tsutomu Nakada
2
Department of Molecular Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
Search for other works by this author on:
Shuichi Mori,
Shuichi Mori
3
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Search for other works by this author on:
Ryosuke Ishida,
Ryosuke Ishida
3
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Search for other works by this author on:
Hiroyuki Kagechika,
Hiroyuki Kagechika
3
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Search for other works by this author on:
Mitsuhiko Yamada
,
Mitsuhiko Yamada
2
Department of Molecular Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
Search for other works by this author on:
Takashi Sakurai
Takashi Sakurai
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Nagomi Kurebayashi
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Takuro Numaga-Tomita
2
Department of Molecular Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
Takuya Kobayashi
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Satoru Okazaki
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Kyosuke Yamashiro
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Tsutomu Nakada
2
Department of Molecular Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
Shuichi Mori
3
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Ryosuke Ishida
3
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Hiroyuki Kagechika
3
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Mitsuhiko Yamada
2
Department of Molecular Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
Takashi Sakurai
1
Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
Correspondence to Takashi Murayama: takashim@juntendo.ac.jp
This work is part of a special issue on Structure and Function of Ion Channels in Native Cells and Macromolecular Complexes.
Received:
July 18 2022
Revision Received:
September 06 2022
Accepted:
October 03 2022
Online Issn: 1540-7748
Print Issn: 0022-1295
Funding
Funder(s):
JPS KAKENHI
- Award Id(s): 19H03404,22H02805,19K07105,22K06652,20K11368
Funder(s):
Japan Agency for Medical Research and Development
- Award Id(s): JP20am0101080,JP20am0101098
Funder(s):
National Center of Neurology and Psychiatry
- Award Id(s): 2-5
Funder(s):
Vehicle Racing Commemorative Foundation
- Award Id(s): 6237,6303
© 2022 Murayama et al.
2022
Murayama et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
J Gen Physiol (2022) 154 (12): e202213230.
Article history
Received:
July 18 2022
Revision Received:
September 06 2022
Accepted:
October 03 2022
Connected Content
Citation
Takashi Murayama, Nagomi Kurebayashi, Takuro Numaga-Tomita, Takuya Kobayashi, Satoru Okazaki, Kyosuke Yamashiro, Tsutomu Nakada, Shuichi Mori, Ryosuke Ishida, Hiroyuki Kagechika, Mitsuhiko Yamada, Takashi Sakurai; A reconstituted depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery. J Gen Physiol 5 December 2022; 154 (12): e202213230. doi: https://doi.org/10.1085/jgp.202213230
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Reconstituting depolarization-induced calcium release
J Gen Physiol (November,2022)
Calcium-induced release of calcium in muscle: 50 years of work and the emerging consensus
J Gen Physiol (March,2018)
Email alerts
Advertisement